CD8A and neoplasm: We have recently demonstrated the robustness of the consensus Immunoscore (IS) assay in accurately stratifying stage II CC patients into IS-high and -low risk subgroups.32,33 Patients within these subgroups have shown significantly divergent clinical outcomes.32,33 IS is an immune digital pathology (DP)-based assay that quantifies CD3+ and CD8+ lymphocyte infiltration density in both the tumor core and invasive margin.